Huntington’s Disease, 
Cannabis, and All the 
Pharmacology in Between

Eileen Denovan-Wright, Ph.D.  
Professor, Associate Dean of Graduate Studies  
Dalhousie University

Robert Laprairie, M.S.c., Ph.D. Candidate  
Department of Pharmacology  
Dalhousie University

Thursday, July 16th 2015  
12:00-1:00 p.m.

Alfond 304  
Biddeford Campus

Lunch will be Provided

Hosted by: John Streicher, Ph.D.  
Sponsored by: The UNECOM Biomedical Sciences Department and the Center for Excellence in the Neurosciences

Dr. Denovan-Wright is a Professor in the Department of Pharmacology and Associate Dean of the Faculty of Graduate Studies at Dalhousie University. Eileen’s current research interests include the pharmacology of cannabinoids, dopamine, and endothelin, transcriptional regulation, and Huntington’s disease. She is currently a member of multiple professional research societies, including the Canadian Society for Neuroscience and an executive board member of the Canadian Council on Animal Care. Eileen obtained her BSc Hon in Biology and PhD from Dalhousie University.

Robert B Laprairie is a PhD student in the Department of Pharmacology at Dalhousie University. He has published 13 manuscripts in peer-reviewed journals, 24 conference abstracts, and 3 patents. Robert’s current research focuses on applying the pharmacological principals of biased agonism and allosteric modulation to the development of novel cannabinoid-based therapeutics. He is the student representative for the International Cannabinoid Research Society and the American Society for Pharmacology and Experimental Therapeutics – Neuropharmacology Division. Robert obtained his BSc Hon in Biochemistry from the University of Saskatchewan and his MSc in Pharmacology and Neuroscience from Dalhousie University.